Search

Author/Creator Plesner, T.

1. DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX). (June 2017)

Authors:
Bahlis, N.J.; Moreau, P.; Nahi, H.; Plesner, T.; Goldschmidt, H.; Suzuki, K.; Orlowski, R.Z.; Rabin, N.; Leiba, M.; Oriol, A.; Chari, A.; San Miguel, J.; Richardson, P.G.; Usmani, S.; O'Rourke, L.; Wu, K.; Casneuf, T.; Chiu, C.; Qin, X.; Dimopoulos, M.A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022)

Authors:
Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
826
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search